Correspondence 0001193125-26-187839 from Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc.
Date: April 28, 2026 · CIK: 0001420565 · Accession: 0001193125-26-187839
AI Filing Summary & Sentiment
Reasoning
Letter
Re : Rein Therapeutics, Inc. Registration Statement on Form S-1 CIK 0001420565 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: Thursday, April 30, 2026 Requested Time: 5:00 p.m., Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “ Securities Act ”), we, the undersigned, as representative of the several underwriters of the proposed public offering of securities of Rein Therapeutics, Inc. (the “ Company ”), hereby join the Company’s request that the effective date of the above-referenced registration statement on Form S-1 be accelerated so that it will be declared effective at 5:00 p.m., Eastern Daylight Time, on April 30, 2026 or as soon thereafter as possible. Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Konik Capital Partners, LLC, a division of T.R. Winston and Company 7 World Trade Center, 46th Floor New York, NY 10007 April 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara
Very truly yours,
KONIK CAPITAL PARTNERS, LLC,
Show Raw Text
CORRESP 1 filename1.htm CORRESP Konik Capital Partners, LLC, a division of T.R. Winston and Company 7 World Trade Center, 46th Floor New York, NY 10007 April 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re : Rein Therapeutics, Inc. Registration Statement on Form S-1 CIK 0001420565 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: Thursday, April 30, 2026 Requested Time: 5:00 p.m., Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “ Securities Act ”), we, the undersigned, as representative of the several underwriters of the proposed public offering of securities of Rein Therapeutics, Inc. (the “ Company ”), hereby join the Company’s request that the effective date of the above-referenced registration statement on Form S-1 be accelerated so that it will be declared effective at 5:00 p.m., Eastern Daylight Time, on April 30, 2026 or as soon thereafter as possible. Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, KONIK CAPITAL PARTNERS, LLC, A DIVISION OF T.R. WINSTON AND COMPANY By: /s/ Alden Carrere Name: Alden Carrere Title: Co-Founder